Notably, our preclinical in vivo studies dosing ripretinib with the murine equivalent to the human dose demonstrate limited activity in GIST xenograft models bearing V654A, the most frequent ATP pocket mutation in KIT, further reinforcing the need for selective KIT inhibitors with potent activity against the broad spectrum of disease-relevant mutations of KIT. Here, KIT is linked to gastrointestinal stromal tumor.